AgingResearch.NewsJoin free

Zag Bio

CompanyUnited States

Zag Bio develops one asset, in phase 1 (ZAG-101 in type 1 diabetes). Mostly other acting on inflammation; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • ZAG-101

    Therapy preserving insulin-producing beta-cell function in autoimmune diabetes.

    Phase 1, Other, Inflammation, type 1 diabetes

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence